The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
ApexOnco Front Page
Recent articles
A fresh licensing deal tidies up years of work between the two companies.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
But PFS data are lacking, and there are questions about first and second-line plans.
Three private biotechs enter clinical trials, one targeting KRAS.
